People: Synta Pharmaceuticals Corp (SNTA.OQ)
SNTA.OQ on NASDAQ Stock Exchange Global Market
6.09USD
1 Aug 2013
6.09USD
1 Aug 2013
Price Change (% chg)
$-0.62 (-9.24%)
$-0.62 (-9.24%)
Prev Close
$6.71
$6.71
Open
$6.64
$6.64
Day's High
$6.90
$6.90
Day's Low
$6.04
$6.04
Volume
617,019
617,019
Avg. Vol
463,669
463,669
52-wk High
$11.77
$11.77
52-wk Low
$3.77
$3.77
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Keith Gollust |
67 | 2002 | Independent Chairman of the Board |
Safi Bahcall |
44 | 2003 | President, Chief Executive Officer, Director |
Keith Ehrlich |
62 | 2006 | Chief Financial Officer, Vice President - Finance and Administration |
Amar Singh |
54 | 2011 | Senior Vice President - Business and Commercial Development, Chief Business Officer |
Vojo Vukovic |
46 | 2009 | Senior Vice President, Chief Medical Officer |
Wendy Rieder |
45 | 2006 | Vice President - Intellectual Property and Legal Affairs, General Counsel |
Bruce Kovner |
68 | 2002 | Independent Director |
Donald Kufe |
68 | 2010 | Independent Director |
William Reardon |
66 | 2004 | Independent Director |
Robert Wilson |
72 | 2003 | Independent Director |
George Farmer |
Vice President - Corporate Development |
Biographies
| Name | Description |
|---|---|
Keith Gollust |
Mr. Keith R. Gollust is Independent Chairman of the Board of Synta Pharmaceuticals Corp. Mr. Gollust has been a member of Board of Directors since July 2002 and has been Chairman since September 2002. Mr. Gollust is a private investor and President of Gollust Management, Inc., the general partner of Wyandanch Partners, an investment partnership. In the past, Mr. Gollust has served as a director of numerous public and private companies. Mr. Gollust currently serves as a director of CastleLine Holdings, LLC, an insurance holding company and Script Relief, LLC, a discount prescription drug company. He also is a member of the Board of Trustees of The Julliard School. Mr. Gollust received a B.A. from Princeton University and an MSIA from Carnegie Mellon University. |
Safi Bahcall |
Dr. Safi R. Bahcall, Ph.D., is President, Chief Executive Officer, Director of Synta Pharmaceuticals Corp. He co-founded Synta with Dr. Lan Bo Chen and has been Chief Executive Officer and a member of Board of Directors since inception in July 2001. Dr. Bahcall has served as President since December 2003. From 1998 to 2001, Dr. Bahcall was a consultant at McKinsey & Company, a management consulting firm, advising investment banks and pharmaceutical companies on strategy, technology, and operations. Dr. Bahcall also co-founded a drug discovery company focused on novel ion channel research in November 2001, which was acquired by Synta in December 2002. He received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. |
Keith Ehrlich |
Mr. Keith S. Ehrlich, CPA, is Chief Financial Officer, Vice President - Finance and Administration of Synta Pharmaceuticals Corp. From November 2003 to February 2004, Mr. Ehrlich served as a financial consultant to the Company. From September 1999 to April 2003, Mr. Ehrlich was Vice President, Finance and Administration and Chief Financial Officer and Treasurer at Argentys Corporation, a private software development company. From January 1998 to July 1999, Mr. Ehrlich served as Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Dyax Corp., a publicly traded biopharmaceutical company. From October 1993 to January 1998, he served as Vice President, Finance and Administration and Chief Financial Officer and Treasurer of Oravax, Inc., a publicly traded biopharmaceutical company since acquired by Acambis plc. From May 1991 to October 1993, he served as Treasurer and Director of Finance of Vertex Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. From January 1980 to April 1991, Mr. Ehrlich was an auditor with Coopers & Lybrand LLP. Mr. Ehrlich received his B.A. in Biology from Drew University and his M.B.A. in Finance and Accounting from Rutgers University. |
Amar Singh |
Mr. Amar Singh is Senior Vice President - Business and Commercial Development, Chief Business Officer of Synta Pharmaceuticals Corp. Prior to joining the company, Mr. Singh was with Spectrum Pharmaceuticals from October 2008 to April 2009, where he most recently served as Chief Operating Officer, and previously as SVP and Chief Commercial Officer. Prior to joining Spectrum, Mr. Singh was Chief Commercial Officer at Novacea from February 2006 to October 2008, where he was responsible for securing partnerships for the company's lead compound, Asentar. Prior to Novacea, Mr. Singh led the launch of the proprietary division of American Pharmaceutical Partners-Abraxis Oncology and provided leadership in all aspects of commercial, and strategic development of the company's flagship product, Abraxane from August 2003 to January 2006. Prior to Abraxis, Mr. Singh held multiple leadership positions in the oncology franchise at Hoffman-La Roche, where he led the launches of several oncology and supportive care products including Xeloda and Kytril. Mr. Singh holds an M.B.A. from the Stern School of Business at New York University and a B.A. from the University of North Carolina. |
Vojo Vukovic |
Dr. Vojo Vukovic, M.D., Ph.D., is Senior Vice President, Chief Medical Officer of Synta Pharmaceuticals Corp. He joined as Vice President, Clinical Research in January 2009, and became Senior Vice President, Chief Medical Officer in July 2009. Dr. Vukovic has over 17 years experience in oncology drug development. Prior to joining the company, he was Global Medical Lead for Sutent® and axitinib in a number of cancer indications at Pfizer from September 2006 to January 2009. Prior to Pfizer, he served in key medical and regulatory roles at Aventis Pasteur from April 2001 to February 2002, Ortho Biotech from February 2002 to September 2003, ILEX Oncology from September 2003 to January 2005, and BioNumerik Pharmaceuticals from January 2005 to June 2006. Over the course of his career, Dr. Vukovic has been responsible for over 100 Phase 1 to Phase 4 clinical studies in cancer indications including melanoma, tumors of the lung, pancreas, breast, colorectal, ovarian, brain, as well as NHL and certain leukemias. Prior to his industry career, Dr. Vukovic was a post-doctoral fellow at the Ontario Cancer Institute, Toronto in Ontario and Institute for Cell Biology in Essen, Germany where he conducted basic and translational research in solid tumor microenvironments and oxidative stress. Dr. Vukovic received his Ph.D. and M.Sc. degrees from the University of Toronto and his M.D. degree from the University of Sarajevo, Bosnia and Herzegovina. |
Wendy Rieder |
Ms. Wendy E. Rieder, Esq., is Vice President - Intellectual Property and Legal Affairs, General Counsel of Synta Pharmaceuticals Corp. In August 1998, Ms. Rieder co-founded Microbiotix, Inc., a privately held biotechnology company developing small-molecule anti-infectives, and served as its Chief Operating Officer and Vice President, Business Development and Intellectual Property from January 2000 to December 2002. From August 1997 to December 1999, Ms. Rieder served as the Vice President, Business Development and Intellectual Property at LipoGenics, Inc., a subsidiary of a publicly traded biopharmaceutical company. Ms. Rieder was a patent attorney at Boehringer Ingelheim Pharmaceuticals, a U.S. affiliate of Boehringer Ingelheim GmbH, a global pharmaceutical company, from August 1995 to July 1997, and a patent agent at Fish & Neave LLP from January 1991 to July 1995. Ms. Rieder received an M.A. in organic chemistry from Columbia University and a J.D. from Fordham Law School. |
Bruce Kovner |
Mr. Bruce Kovner is Independent Director of Synta Pharmaceuticals Corp. In 1983, Mr. Kovner founded Caxton Corporation, a diversified trading company and manager of client funds active in currency, interest rate, commodity and equity markets, and has acted as its Chairman since its inception. He is also the former Chairman of Caxton Associates LP, from which he retired in December 2011. He is now Chairman of Caxton Alternative Management LP, which he established in January 2012 to manage his investment trading and business activities. Prior to the formation of Caxton, Mr. Kovner served as a Vice President of Commodities Corporation, a private commodities trading company since acquired by Goldman Sachs. Mr. Kovner is Chairman of the Board of Trustees of the Juilliard School, and Vice Chairman of the Board of Directors of Lincoln Center for the Performing Arts. He also serves on the Board of the American Enterprise Institute, and the Institute for Advanced Study, and is a Managing Director of the Metropolitan Opera. Mr. Kovner received his B.A. from Harvard College in 1966. He continued his studies at the John F. Kennedy School of Government until 1970. |
Donald Kufe |
Dr. Donald W. Kufe, M.D., is Independent Director of Synta Pharmaceuticals Corp. Dr. Kufe is a Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School Department. Dr. Kufe received his M.D. from the University of Rochester School of Medicine. After a clinical fellowship in medical oncology at Dana-Farber Cancer Institute, he joined the staff in 1979. He has served as chief of the Division of Cancer Pharmacology, deputy director of the Dana-Farber/Harvard Cancer Center, director of the Harvard Phase I Oncology Group and leader of the Experimental Therapeutics Program. He is an editor of the textbook "Cancer Medicine." Dr. Kufe is the recipient of the Richard P. and Claire W. Morse Scientific Award, DFCI, the Scholar Award, Burroughs-Wellcome and the Faculty Research Award, American Cancer Society. Dr. Kufe currently sits on the Board of Directors of Genus Oncology, LLC and Linus Pharmaceuticals, Inc., and from December 2003 to July 2009, he served as a director of Adherex Technologies Inc., a publicly traded biopharmaceutical company. |
William Reardon |
Mr. William S. Reardon, CPA., is Independent Director of Synta Pharmaceuticals Corp. Until his retirement in 2002 from PricewaterhouseCoopers LLP, an international accounting firm, where he was employed from June 1973 to July 2002, Mr. Reardon was a business assurance (audit) partner at the firm's Boston office and leader of its life sciences industry practice for New England and the eastern United States. From 1998 to 2000, Mr. Reardon served on the board of the emerging companies section of the Biotechnology Industry Organization. He also served on the board of the Massachusetts Biotechnology Council from 2000 until his retirement in 2002. Mr. Reardon is currently a member of the Board of Directors and the chairman of the audit committee of Idera Pharmaceuticals, Inc., a publicly traded pharmaceutical company, and from 2003 to 2010 served in the same capacity for Oscient Pharmaceuticals Corporation, another publicly traded pharmaceutical company. In April 2010, Mr. Reardon joined the Board of Trustees of H&Q Life Sciences Investors and H&Q Healthcare Investors, two closed-end publicly held mutual funds. Mr. Reardon received both his undergraduate degree in East Asian history and his M.B.A. from Harvard University. |
Robert Wilson |
Mr. Robert N. Wilson is Independent Director of Synta Pharmaceuticals Corp. Mr. Wilson is Chairman of MEVION Medical Systems (formerly Still River Systems), a medical device company. Prior to his association with MEVION, Mr. Wilson was Chairman of Caxton Health Holdings, LLC, from 2004 through 2007 and was Vice Chairman of the Board of Directors of Johnson & Johnson, a manufacturer of healthcare products, from 1989 until 2003. Mr. Wilson had joined Johnson & Johnson in 1964. Mr. Wilson is also a director of Hess Corporation, an integrated oil and gas company and Charles Schwab Corporation, a publicly traded financial services company. |
George Farmer |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Keith Gollust |
-- |
Safi Bahcall |
2,059,290 |
Keith Ehrlich |
624,554 |
Amar Singh |
804,179 |
Vojo Vukovic |
900,181 |
Wendy Rieder |
622,938 |
Bruce Kovner |
-- |
Donald Kufe |
-- |
William Reardon |
-- |
Robert Wilson |
-- |
George Farmer |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Keith Gollust |
0 | 0 |
Safi Bahcall |
150,000 | 0 |
Keith Ehrlich |
54,545 | 218,180 |
Amar Singh |
0 | 0 |
Vojo Vukovic |
0 | 0 |
Wendy Rieder |
14,340 | 0 |
Bruce Kovner |
0 | 0 |
Donald Kufe |
0 | 0 |
William Reardon |
0 | 0 |
Robert Wilson |
0 | 0 |
George Farmer |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
KOVNER BRUCE S |
8,000 | $0.00 |
KUFE DONALD W |
8,000 | $0.00 |
GOLLUST KEITH R |
1,000 | $0.00 |
WILSON ROBERT N |
2,000 | $0.00 |
KOVNER BRUCE S |
1,000 | $0.00 |
KOVNER BRUCE S |
1,000 | $0.00 |
REARDON WILLIAM S |
4,000 | $0.00 |
GOLLUST KEITH R |
8,000 | $0.00 |
GOLLUST KEITH R |
2,000 | $0.00 |
GOLLUST KEITH R |
1,000 | $0.00 |
GOLLUST KEITH R |
4,000 | $0.00 |
BAHCALL SAFI R |
10,000 | $5.03 |
KOVNER BRUCE S |
150,000 | $4.71 |
KOVNER BRUCE S |
300,000 | $4.65 |
KOVNER BRUCE S |
200,000 | $4.35 |
KOVNER BRUCE S |
200,000 | $4.43 |
BAHCALL SAFI R |
20,000 | $4.12 |
KOVNER BRUCE S |
50,000 | $4.23 |
KOVNER BRUCE S |
200,000 | $4.00 |
BAHCALL SAFI R |
10,000 | $4.06 |
KOVNER BRUCE S |
738,900 | $4.31 |
BAHCALL SAFI R |
10,000 | $4.04 |
KOVNER BRUCE S |
756,000 | $4.71 |
VUKOVIC VOJISLAV |
10,000 | $4.58 |
WILSON ROBERT N |
10,000 | $5.00 |

